Rita Leykin

Array ( [id] => 20425270 [patent_doc_number] => 20250387357 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-25 [patent_title] => MIRDAMETINIB TREATMENT [patent_app_type] => utility [patent_app_number] => 19/237465 [patent_app_country] => US [patent_app_date] => 2025-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19237465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20033233 [patent_doc_number] => 20250171455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-29 [patent_title] => MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 19/030481 [patent_app_country] => US [patent_app_date] => 2025-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19030481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20014348 [patent_doc_number] => 20250152570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-15 [patent_title] => Uses of Selonsertib in the Preparation of Drugs for the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 19/019396 [patent_app_country] => US [patent_app_date] => 2025-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19019396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20663600 [patent_doc_number] => 12605349 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-21 [patent_title] => Methods of treating grade 3 astrocytoma [patent_app_type] => utility [patent_app_number] => 18/977389 [patent_app_country] => US [patent_app_date] => 2024-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 29492 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18977389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19998393 [patent_doc_number] => 20250136615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-01 [patent_title] => SMALL MOLECULE INHIBITORS OF KRAS PROTEINS [patent_app_type] => utility [patent_app_number] => 18/920212 [patent_app_country] => US [patent_app_date] => 2024-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18053 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18920212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20425265 [patent_doc_number] => 20250387352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-25 [patent_title] => MIRDAMETINIB TREATMENT [patent_app_type] => utility [patent_app_number] => 18/912328 [patent_app_country] => US [patent_app_date] => 2024-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18167 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18912328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20425266 [patent_doc_number] => 20250387353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-25 [patent_title] => MIRDAMETINIB TREATMENT [patent_app_type] => utility [patent_app_number] => 18/912341 [patent_app_country] => US [patent_app_date] => 2024-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18912341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19798899 [patent_doc_number] => 20250064824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 18/731923 [patent_app_country] => US [patent_app_date] => 2024-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10084 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18731923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462333 [patent_doc_number] => 20240316002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => Cannabinoid-Containing Formulations for Parkinsonian Movement Disorders [patent_app_type] => utility [patent_app_number] => 18/679418 [patent_app_country] => US [patent_app_date] => 2024-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -107 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18679418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19754361 [patent_doc_number] => 20250042926 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-06 [patent_title] => THERAPEUTIC COMPOUNDS FOR HIV [patent_app_type] => utility [patent_app_number] => 18/678444 [patent_app_country] => US [patent_app_date] => 2024-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50580 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18678444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19401426 [patent_doc_number] => 20240284937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVE [patent_app_type] => utility [patent_app_number] => 18/634899 [patent_app_country] => US [patent_app_date] => 2024-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10786 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18634899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387837 [patent_doc_number] => 20240277707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus [patent_app_type] => utility [patent_app_number] => 18/616625 [patent_app_country] => US [patent_app_date] => 2024-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18616625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111182 [patent_doc_number] => 20240122932 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => Methods of Treating B-Cell Malignancy Using Bcl-2 Inhibitor [patent_app_type] => utility [patent_app_number] => 18/524170 [patent_app_country] => US [patent_app_date] => 2023-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18524170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065588 [patent_doc_number] => 20240100014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => THERAPEUTIC FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/492718 [patent_app_country] => US [patent_app_date] => 2023-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18492718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18973241 [patent_doc_number] => 20240053333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => CHEMICAL MODIFICATION OF ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF [patent_app_type] => utility [patent_app_number] => 18/364200 [patent_app_country] => US [patent_app_date] => 2023-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18364200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050856 [patent_doc_number] => 20240092825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS [patent_app_type] => utility [patent_app_number] => 18/361001 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18361001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19202791 [patent_doc_number] => 20240174690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/314445 [patent_app_country] => US [patent_app_date] => 2023-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18314445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19624092 [patent_doc_number] => 12162896 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Salts and polymorphs of certain MCL-1 inhibitors [patent_app_type] => utility [patent_app_number] => 18/311708 [patent_app_country] => US [patent_app_date] => 2023-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 58 [patent_no_of_words] => 22119 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18311708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953554 [patent_doc_number] => 20240041881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/141965 [patent_app_country] => US [patent_app_date] => 2023-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18141965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18970485 [patent_doc_number] => 20240050577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/139692 [patent_app_country] => US [patent_app_date] => 2023-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83245 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18139692 [rel_patent_id] =>[rel_patent_doc_number] =>)